Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma

References

• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817–2825.
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome. Cancer Res. 2007;67(13):6383–6391.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3(9):e143.
   PubMed Web of Science ®Google Scholar
• Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events. Clin Cancer Res. 2011;17(9):2734–2743.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013;122(14):2305–2309.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2009;24(1):22–32.
   PubMed Web of Science ®Google Scholar
• Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114(16):3439–3447.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau J-L, et al. Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2012;30(16):1953–1959.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Offidani M, Pegourie B, et al. A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2015;33(Suppl):Abs 8573.
   Google Scholar
• Lokhorst H, Plesner T, Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2013;31(Suppl):Abs 8512.
   Google Scholar
• Plesner T, Arkenau T, Lokhorst H, et al. Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma. Blood. 2013;122(21):1986–1986.
   Google Scholar
• Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013;14(11):1129–1140.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VTM, Yoon -S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013;3(11):e162.
   PubMed Web of Science ®Google Scholar
• Garderet L, Iacobelli S, Moreau P, et al. Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475–2482.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. N Engl J Med. 1999;341(21):1565–1571.
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132(5):584–593.
   PubMed Web of Science ®Google Scholar
• Von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2008;81(4):247–252.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J Off J Eur Haematol Assoc EHA. 2004;5(2):112–117.
   Google Scholar
• García-Sanz R, González-Porras JR, Hernández JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18(4):856–863.
   PubMed Web of Science ®Google Scholar
• Offidani M, Bringhen S, Corvatta L, et al. Thalidomide–dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide–dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol. 2007;78(4):297–302.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades C, Ghobrial I, et al. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006;18(6):598–608.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589–1596.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. The Lancet. 2010;376(9758):2075–2085.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med. 2007;357(21):2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2007;357(21):2123–2132.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11):1968–1975.
   PubMed Web of Science ®Google Scholar
• Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013;122(16):2799–2806.
   PubMed Web of Science ®Google Scholar
• Baz R, Martin TG, Alsina M, et al. Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study. Blood. 2014;124(21):303–303.
   Google Scholar
• Lacy MQ, LaPlant BR, Laumann KM, et al. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Blood. 2014;124(21):304–304.
   Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma. Blood. 2013;122(21):690–690.
   Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma. Blood. 2015;126(20):2284–2290.
   Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med. 2005;352(24):2487–2498.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557–3560.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91(7):929–934.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377–2380.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: combination Therapy Improves Time to Progression. J Clin Oncol. 2007;25(25):3892–3901.
   PubMed Web of Science ®Google Scholar
• Gozzetti A, Fabbri A, Oliva S, et al. Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2010;10(1):68–72.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol. 2008;19(6):1160–1165.
   PubMed Web of Science ®Google Scholar
• Waterman GN, Yellin O, Swift RA, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Ann Hematol. 2010;90(2):193–200.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123(10):1461–1469.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014;123(7):985–991.
   PubMed Web of Science ®Google Scholar
• Rodon P, Hulin C, Pegourie B, et al. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica. 2015;100(2):e56–e59.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047–1055.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457–2466.
   PubMed Web of Science ®Google Scholar
• Teo EC, Chew Y, Phipps C. A review of monoclonal antibody therapies in lymphoma. Crit Rev Oncol Hematol. 2015. pii:S1040-8428(15)30030-5. DOI:10.1016/j.critrevonc.2015.08.014. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2012;30(16):1960–1965.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Plesner T, Arkenau H-T, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. ASCO Meet Abstr. 2014;32(15_suppl):8533.
   Google Scholar
• Plesner T, Arkenau H-T, Lokhorst HM, et al. Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. Blood. 2014;124(21):84–84.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mateos M-V, Bladé J, et al. An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. Blood. 2014;124(21):176–176.
   PubMed Web of Science ®Google Scholar